Specifying and Treating Anxiety in Autism Research

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions
Autism Spectrum DisorderAnxiety
Interventions
DRUG

Sertraline

Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.

BEHAVIORAL

CBT/BIACA

Participants receive 16 weeks of BIACA therapy.

DRUG

Placebo

Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.

Trial Locations (1)

95817

UC Davis MIND Institute, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER

NCT03279471 - Specifying and Treating Anxiety in Autism Research | Biotech Hunter | Biotech Hunter